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Abstract
Background: Postoperative respiratory complications are a major cause of mortality following liver transplantation (LT).
Noninvasive ventilation (NIV) appears to be effective for respiratory complications in patients undergoing solid organ
transplantation; however, mortality has been high in patients who experienced reintubation in spite of NIV therapy. The
predictors of reintubation following NIV therapy after LT are not exactly known.
Methods: Of 511 adult patients who received living-donor LT, data on the 179 who were treated by NIV were retrospectively
examined.
Results: Forty-three (24%) of the 179 patients who received NIV treatment required reintubation. Independent factors
associated with reintubation by multivariate logistic regression analysis were controlled preoperative infections (odds ratio
[OR] 8.88; 95% confidence interval (CI) 1.64 to 48.11; p = 0.01), ABO-incompatibility (OR 4.49; 95% CI, 1.50 to 13.38; p = 0.007),
and presence of postoperative pneumonia at the time of starting NIV (OR 3.28; 95% CI, 1.02 to 11.01; p = 0.04). The
reintubated patients had a significant higher rate of postoperative infectious complications and a significantly longer
intensive care unit stay than those in whom NIV was successful (p,0.0001). Of the 43 reintubated patients, 22 (51.2%) died
during hospitalization following LT vs. 8 (5.9%) of the 136 patients in whom NIV was successful (p,0.0001).
Conclusions: Because controlled preoperative infection, ABO-incompatibility or pneumonia prior to the start of NIV were
independent risk factors for reintubation following NIV, caution should be used in applying NIV in patients with these
conditions considering the high rate of mortality in patients requiring reintubation following NIV.
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Introduction
Liver transplantation (LT) has become the mainstay for the
treatment of end-stage liver disease, acute liver failure, hepatocel-
lular cancer, and some metabolic liver diseases [1]. Liver
transplantation in Japan is highly dependent on living donors
because of a severe deficiency in the availability of liver grafts from
deceased donors [2].
Postoperative respiratory complications (PRCs) such as atelec-
tasis, pleural effusion, pulmonary edema, and pneumonia are
frequent after LT and their incidence is reported to be between
44% and 87% [3–8]. Furthermore, persistent pulmonary edema,
pleural effusion, and atelectasis have been reported to be major
independent predictors of post-transplant pneumonia [5]. Thus,
PRCs after transplantation negatively impact mortality [3,4,6],
with recent data showing a mortality rate of 40% [9].
Noninvasive ventilation (NIV) is an effective treatment for acute
respiratory failure in many conditions [10–14]. Two randomized
controlled studies showed its effectiveness in patients with acute
respiratory failure under immunosuppressed conditions [11,14].
On the other hand, in immunosuppressed patients who failed
NIV, the rate of hospital mortality was reported to be very high,
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ranging from 62% to 100% [11,15,16]. Recent data on patients
with hematologic malignancies showed that the reintubation rate
with NIV was almost 50% and that the mortality rate following
NIV failure amounted to 69–79% [15,17]. The respiratory rate
during NIV and a longer delay between admission and its first use
of NIV as well as other factors were significantly associated with
NIV failure [15]. However, factors related to reintubation
following NIV for patients with PRCs after LT have not been
documented well. In our hospital, we have successfully begun to
apply NIV for respiratory complications in patients with living
donor liver transplantation (LDLT) [18–21]. Although we have
subsequently experienced many more cases (over 200 cases) for
whom NIV was used following LDLT, reintubation has been
necessary in some of these patients. Therefore, to decrease the rate
of reintubation following NIV treatment after LDLT and to
achieve a better prognosis, we have retrospectively examined
patient data to elucidate the factors necessitating reintubation
following NIV treatment. We also compared clinical outcomes
between patients who did and did not require reintubation after
NIV treatment following LT.
Methods
Patients
From August 1999 to July 2008, 532 liver transplant recipients,
aged 13 years or over, underwent LDLT at Kyoto University
Hospital. Of the 200 patients who subsequently received NIV, we
excluded 21 who discontinued NIV therapy because of reopera-
tion (regardless of their respiratory status) and analyzed data on
the remaining 179 patients. Fifteen of the 179 patients had
infections that could be expected to be successfully treated before
LT but that did result in postponement of the LT. These patients
received LT after the infections were controlled as evidenced by
reduced fever, blood cultures negative for bacteria, and resolution
of conditions such as pneumonia, peritonitis, cholangitis, phleg-
mon, or enterocolitis.
After LDLT, all patients entered the Intensive Care Unit (ICU)
and required invasive mechanical ventilation before weaning.
Extubation was considered under the following conditions: 1)
clinically stability; 2) improvement in underlying disease and its
complications had improved; 3) minimal ventilator support was
Table 1. Operative and postoperative status of 179 recipients of NIV.
Overall (n =179) Reintubation (n =43) NIV Success (n =136) p value
ABO Incomptible 45 (25.1) 17 (39.5) 28 (20.6) 0.01
APACHE II 16.464.3 18.564.8 15.763.9 0.0001
Postoperative data:
Hb (g/dl) 9.461.8 8.761.6 9.661.8 0.005
Total bilirubin (mg/dl) 7.367.2 11.869.4 5.865.7 ,0.0001
CRP (mg/dl) 4.363.6 5.664.0 3.963.4 0.005
Na(mEq/l) 135.764.6 134.164.4 136.164.6 0.01
HR (beats per minute) 92618 100619 89617 0.0009
RR (beats per minute) 1968 2268 1867 0.008
Reintubation before NIV 19 (10.6) 9 (20.9) 10 (7.4) 0.02
Extubation (days) 3.465.3 6.668.1 2.463.5 ,0.0001
From Extubation to NIV(days) 2.767.7 2.967.9 2.666.3 0.80
Reasons for NIV:
PaO2/FIO2 #250 95 (53.1) 20 (46.5) 75 (55.1) 0.32
PaCO2 $45 Torr 40 (22.3) 9 (20.9) 31 (22.8) 0.80
Pneumonia on NIV 24 (13.4) 12 (27.9) 12 (8.8) 0.001
Respiratory rate $25/min 28 (15.6) 11 (25.6) 17 (12.5) 0.04
Atelectasis 31 (17.3) 4 (9.3) 27 (19.9) 0.11
Massive pleural effusion 96 (53.6) 25 (58.1) 71 (52.2) 0.50
Other reasons 27 (15.1) 8 (18.6) 19 (14.0) 0.46
Settings of NIV:
Mode (S/T/ST) 1/1/177 0/1/42 1/0/135 0.17
IPAP (cmH2O) 8.861.5 9.061.6 8.761.5 0.26
EPAP (cmH2O) 4.661.3 4.260.5 4.360.6 0.54
Amount of oxygen (l/min) 8.863.4 9.763.2 8.563.4 0.04
mean 6 SD or number (%) Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; Hb, hemoglobin; CRP, C reactive protein; Na, sodium; HR, heart
rate; RR, respiratory rate; NIV, noninvasive ventilation; LDLT, living-donor liver transplantation; PaO2, partial pressure of arterial oxygen; FIO2, fraction of inspired oxygen;
PaCO2, partial pressure of arterial carbon dioxide; S, spontaneous; T, timed; ST, spontaneous and timed; IPAP, inspiratory positive airway pressure; EPAP, expiratory
positive airway pressure.
doi:10.1371/journal.pone.0081417.t001
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minimal (pressure support ,6 cm H2O with positive end-
expiratory pressure (PEEP) #4 cm H2O); and 4) sufficient
spontaneous breathing was sufficient. The Ethics Committee of
Kyoto University gave approval for the protocol of this study.
Introduction of NIV
NIV was considered for all patients who received oxygen
therapy or were in case of reintubation and mechanical ventilation
and who met at least one of the following criteria to indicate
serious PRCs: 1) ratio of the partial pressure of arterial oxygen
(PaO2) to the fraction of inspired oxygen (FIO2) (PaO2/FIO2)#250
while the patient was receiving oxygen therapy; 2) partial pressure
of arterial carbon dioxide (PaCO2) $45 Torr; 3) presence of
pneumonia while on oxygen therapy; 4) respiratory rate .25
breaths per minute with active contraction of accessory muscles of
respiration and/or paradoxical thoraco-abdominal motion; 5)
atelectasis of more than one lobe; 6) massive or uncontrolled
pleural effusion after percutaneous thoracic drainage, because
some of the effusion might be ascites from the abdomen by the
pressure gradient [22] ; and 7) other reasons. FIO2 of oxygen
therapy via a nasal cannula, face mask, or reservoir face mask was
calculated based on a previously published method [23]. Patients
who required urgent intubation due to respiratory arrest,
respiratory pauses, severe hepatic coma (above Grade 2), copious
tracheal secretion and hemodynamic instability were not started
on NIV.
Noninvasive Ventilation
We used a full-face mask or a nasal mask (Resmed, North Ryde,
New South Wales, Australia) for NIV. Ventilation in all patients
was by bilevel positive airway pressure (bilevel PAP) devices with
oxygen and humidification (VPAP series Resmed) [18–21,24,25].
After the mask had been secured, the level of support pressure and
expiratory positive airway pressure (EPAP) and the amount of
oxygen were progressively increased until SaO2 was .95%,
accompanied by decreased respiratory rates and/or reduced
activity of accessory muscles for respiration, decreased paradoxical
thoraco-abdominal movement, and improvement in respiratory
discomfort. When applying NIV, a doctor stayed at the bedside
and observed the patient carefully while the SaO2 and electro-
cardiogram were monitored. Throughout the first hour, the
patient’s condition was assessed repeatedly. For minor complica-
tions of NIV treatment such as skin rash, eye irritation, discomfort
from the mask, air pressure, or gastric insufflations, we decreased
the pressure and/or usage time of NIV, used another mask, or
inserted a gastric tube. To calculate the FIO2 during NIV, we used
the value from the information supplied by the manufacturer and
was attached to the mask. Using this information, the FIO2 was
determined from the following parameters: leakage flow rate per
minute from the mask at each pressure and the oxygen flow rate
per minute during NIV. If the leakage flow rate at the setting was
X and the oxygen flow rate was Y, FIO2 at the setting was:
FIO2= {Y61.0+(X2Y)60.21}/X [20].
Discontinuation of NIV
Patients for whom NIV could be discontinued because their
respiratory status (including chest X-ray abnormality) had
improved were assigned to the success group. The reintubated
group was comprised of patients for whom NIV was not successful
and who underwent reintubation with mechanical ventilation were
assigned to the reintubated group. Criteria for reintubation were
as follows; failure to maintain SaO2 of .90% with a FIO2 $0.6;
development of conditions necessitating endotracheal intubation
to protect the upper airway (seizure, severe hepatic coma);
development of copious tracheal secretions that could not be
expectorated; increase in the PaCO2 accompanied by a pH of
#7.30; and severe hemodynamic instability defined as systolic
blood pressure ,70 mmHg.
Data Collection
Pneumonia was defined as new onset of pulmonary infiltrates
with clinical symptoms (fever, cough, purulent tracheobronchial
secretions, and dyspnea at rest), leukocytosis, and detection of
potentially pathogenic bacteria in the sputum or bronchoalveolar
lavage culture. Other infectious complications were wound
infection, liver abscess, subphrenic abscess, cholangitis, peritonitis,
and urinary tract infection. These were confirmed by clinical
observation (fever, purulent discharge from wound, abdominal
pain), and laboratory markers of inflammation with positive
cultures (blood, bile, pus, and urine), and findings from chest X-
rays and/or chest computed tomography. The Acute Physiology
and Chronic Health Evaluation (APACHE) II score was used to
assess the severity of illness at ICU admission [26]. Postoperative
laboratory data presented in Table 1 represent values that were
Table 2. Preoperative characteristics of 179 recipients of NIV.
Overall (n = 179) Reintubation (n =43) NIV Success (n =136) p value
Male 92 (51.4) 19 (44.2) 73 (53.7) 0.28
Age (years) 48.2613.2 48.7612.5 44.3615.7 0.19
Underlying disease: 0.13
Hepatitis B or C, PBC,
Fulminant hepatitis and others
Preoperative status:
Residence in ICU with intubation before LT 23 (12.8) 11 (25.6) 12 (8.8) 0.004
Child-Pugh (points) 10.362.0 10.862.0 10.161.9 0.06
MELD score 24.2611.0 28.1612.1 22.9610.3 0.006
Chest X-ray abnormality: 37 (20.7) 13 (30.2) 24 (17.6) 0.08
Controlled pre-OP infections 15 (8.4) 8 (18.6) 7 (5.1) 0.01
mean 6 SD or number (%).
Abbreviations: ICU, Intensive Care Unit; LT, liver transplantation; MELD, model for end-stage liver disease; pre-OP, preoperative.
doi:10.1371/journal.pone.0081417.t002
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obtained on the morning of the introduction of NIV. Arterial
blood gases were obtained before the introduction of NIV, and
also at the initial assessment after applying NIV (mean time 6
standard deviation (SD) following NIV introduction:
3.964.4 hours). At the initial assessment after NIV, we could
not obtain arterial blood gas in 13 of the 179 patients (7.3%).
Statistical Analysis
Data were analyzed using JMP 9.0 (SAS Institute, Inc. Cary,
NC, USA), and values are expressed as mean 6 SD or absolute
numbers and percentages in each group. We compared the
association between the perioperative factors and the results of
NIV (success group or reintubated group). Continuous variables
were tested by the unpaired t test or Mann-Whitney U test.
Categorical variables were compared using the x2 test or the
Fisher’s exact test. A p value ,0.05 was considered to indicate
statistical significance. Next, we investigated the associations
between perioperative factors and reitubation. Possible predictors
of reintubation were tested by univariate and multivariate logistic
regression analysis. In the logistic regression analysis for reintuba-
tion, variables entered in the multivariate analysis were those
yielding a p value ,0.05 by univariate analysis; p values ,0.05 in
the multivariate analysis were considered statistically significant.
Results
Preoperative and Postoperative Characteristics of the
Patients with NIV
The preoperative characteristics and operative and postopera-
tive status of the 179 recipients of NIV are summarized in Tables 1
and 2, respectively. The mean model for end-stage liver disease
(MELD) score was 24.2611.0 in the 179 patients. Fifteen patients
had controlled preoperative infections; 5 pneumonia, 7 spontane-
ous bacterial peritonitis (SBP), and 1 either cholangitis, phlegmon,
or enterocolitis. As mentioned above, these preoperative infections
had been controlled before the LT (controlled preoperative
infections) (Table 2). Before NIV treatment, 19 (10.6%) of the
179 patients had been reintubated following the LT for the
Table 3. Outcome of 179 hospitalized recipients of NIV.
Overall (n = 179) Reintubation (n =43) NIV Success (n =136) p value
PaO2/FIO2 before NIV 2556114 2636125 2526110 0.60
PaO2/FIO2 after NIV 3286117 3016120 3386115 0.07
PaCO2 before NIV 4167 4167 4267 0.55
PaCO2 after NIV 4166 4167 4266 0.33
NIV intolerant 16 (8.9) 7 (16.3) 9 (6.6) 0.06
Could not tolerate NIV 9 (5.0) 5 (11.6) 4 (2.9) 0.04
Suspended NIV due to complications 7 (3.9) 2 (4.7) 5 (3.7) 0.99
Hospital mortality, due to: 30 (16.8) 22 (51.2) 8 (5.9) ,0.0001
Respiratory complications 14 (7.8) 11 (25.6) 3 (2.2) ,0.0001
Pneumonia 9 (5.0) 8 (18.6) 1 (0.7) ,0.0001
Aspergillosis 3 (1.7) 2 (4.7) 1 (0.7) 0.56
Hemorrhage 2 (1.1) 1 (2.3) 1 (0.7) 0.42
Others: 16 (8.9) 11 (25.6) 5 (3.7) ,0.0001
Graft failure 6 (3.4) 2 (4.7) 4 (2.9) 0.63
Cerebral diseases 2 (1.1) 1 (2.3) 1 (0.7) 0.42
Sepsis 4 (2.2) 4 (9.3) 0 0.003
Gastrointestinal bleeding 4 (2.2) 4 (9.3) 0 0.003
Hospitalization (days) 75.5663.8 103.6698.0 66.7645.2 0.0008
ICU stay (days) 9.2611.1 19.7615.7 5.966.4 ,0.0001
Duration of NIV (days) 13.4614.3 6.366.6 15.6615.3 0.0001
Postoperative infections 89 (49.7) 36 (83.8) 53 (39.0) ,0.0001
Respiratory 47 (26.3) 32 (74.4) 15 (11.0) ,0.0001
Others 66 (36.7) 21 (48.8) 45 (33.1) 0.06
Reoperation 49 (27.3) 21 (48.8) 28 (20.6) 0.0003
HAT 5 (2.8) 2 (4.7) 3 (2.2) 0.60
Biliary leak 12 (6.7) 4 (9.3) 8 (5.9) 0.49
Acute cellular rejection 28 (15.6) 6 (14.0) 22 (16.2) 0.81
Ileus 4 (2.2) 0 4 (2.9) 0.57
ARF after LT 15 (8.4) 5 (11.6) 10 (7.4) 0.36
mean 6 SD or number (%).
Abbreviations: NIV, noninvasive ventilation; PaO2, partial pressure of arterial oxygen; FIO2, fraction of inspired oxygen; PaCO2, partial pressure of arterial carbon dioxide;
NIV, noninvasive ventilation; ARDS, Acute Respiratory Distress Syndrome; ICU, Intensive Care Unit; HAT, hepatic artery thrombosis; ARF, acute renal failure; LT, liver
transplantation.
doi:10.1371/journal.pone.0081417.t003
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following reasons: copious amounts of sputum that could not be
expectorated, septic shock, pneumonia, tracheal hemorrhage, and
respiratory muscle fatigue. NIV was introduced following the
second extubation in these 19 patients (Table 1).
Noninvasive Ventilation
Reasons for application of NIV are listed in Table 1.
Concerning the duration of the initial application of NIV, 137
patients (87.3%) received NIV continuously throughout the day,
17 (10.8%) 2 or 3 times per day, 1–2 hours per NIV session, and 3
(1.9%) only nocturnally. In 43 patients (24.0%), reintubation
following NIV was required for the following reasons: refractory
hypoxemia with pneumonia (n = 17, 39.5%), acute respiratory
distress syndrome (ARDS) (n = 2, 4.7%), secretions that could not
be cleared (n= 12, 27.9%), unconsciousness (n = 6, 14.0%), septic
shock (n = 2), CO2 narcosis (n = 1, 2.3%), excessive tachypnea
(n = 1), re-expansion pulmonary edema (n= 1), and rupture of an
esophageal varix (n = 1).
Outcomes of Patients with NIV Treatment
Table 3 shows the outcome of the NIV treatment. No evidence
of an obvious delay in reintubation was noted, and no severe
complications such as pneumothorax, hypotension, or aspiration
pneumonia were related to NIV treatment.
In both the success and reintubation groups, the baseline PaO2/
FIO2 values were similar and the PaO2/FIO2 at the initial
assessment after NIV therapy was higher in the success group than
in the reintubation group but without significance (p= 0.07)
(Table 3). However, a sub-analysis showed that in patients with
pneumonia prior to application of NIV, the baseline PaO2/FIO2
was similar between groups (success group: n= 12, 284.46118.2
vs. reintubation group: n = 12, 231.76163.0, p = 0.37), whereas
PaO2/FIO2 at the initial assessment after NIV therapy was higher
in the success group than in the reintubation group (success group:
n = 12, 376.86140.1 vs. reintubation group: n= 12, 263.66129.4,
p = 0.04).
Although there was no significant between-group differences in
the mean changes in PaCO2 at the initial assessment after the start
of NIV therapy (Table 3), PaCO2 levels after NIV treatment
significantly decreased in patients with PaCO2 $45 Torr (success
group: n= 27, 51.064.5 Torr to 48.865.3 Torr, p= 0.008;
reintubation group: n= 7, 52.367.2 Torr to 48.465.6 Torr,
p = 0.02).
Eight (5.9%) of the 136 patients in whom NIV was successful
died during hospitalization, while 22 (51.2%) of the 43 patients
who failed NIV treatment died (p,0.0001). NIV treatment could
not be continued in 16 patients for various reasons. In 7 of the 16
patients, NIV was suspended due to complications (6 severe
abdominal distension despite a nasal gastric tube; 1 concomitant
ileus). Nine patients could not tolerate NIV, and the prevalence of
those who could not tolerate NIV was significantly higher in
reintubation group than in NIV success group (Table 3). Among
the 16 patients in whom NIV discontinued, 7 were eventually
reintubated and 5 of those 7 died.
The survival curve shows that patients in the reintubation group
had a significantly poorer prognosis than those in the NIV success
group (p= 0.0009) (Figure 1). Also, patients who failed NIV had
significant longer ICU stays (19.7615.7 days vs. 5.966.4,
p,0.0001).
Logistic Regression Analysis for reintubation
Among the 40 perioperative factors (those listed in Tables 1 and
2 and NIV intolerance), 16 had a significant association with
reintubation in the univariate analysis (Table 4). In the multivar-
iate forward logistic analysis of factors related to reintubation,
controlled preoperative infections (odds ratio [OR] 8.88; 95%
confidence interval (CI) 1.64 to 48.11; p = 0.01), ABO-incompat-
ibility (OR 4.49; 95% CI, 1.50 to 13.38; p = 0.007), and
postoperative pneumonia prior to starting NIV (OR 3.28; 95%
Figure 1. Survival curve following LDLT in NIV success group and reintubation group. Patients who failed NIV had a significantly poorer
prognosis (p = 0.0009). Abbreviations: LDLT, living-donor liver transplantation; NIV, noninvasive ventilation.
doi:10.1371/journal.pone.0081417.g001
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CI, 1.02 to 11.01; p = 0.04) were significant risk factors for
reintubation (Table 5). The R square in this model was 0.299. If
the 19 patients who were administered NIV following the second
extubation were excluded from the study, the same three
conditions were also significant risk factors for reintubation:
controlled preoperative infections (odds ratio [OR] 7.12; 95%
confidence interval (CI) 1.46 to 34.81; p = 0.02), ABO-incompat-
ibility (OR 3.49; 95% CI, 1.03 to 11.83; p = 0.04), and
postoperative pneumonia prior to starting NIV (OR 3.75; 95%
CI, 1.12 to 12.56; p= 0.03).
Discussion
Although the data were retrospective, this study of a large NIV
series in one hospital showed the following significant factors that
were predictive of reintubation following NIV: controlled preop-
erative infections, ABO blood type incompatibility, and postop-
erative pneumonia prior to placement on NIV. After excluding
from the analysis the 19 patients who were reintubated following
LDLT and were provided NIV after that second extubation, those
three factors remained significant. In addition, after the start of
NIV treatment in pneumonia patients, there was a significant
difference not in the initial PaO2/FIO2 but in the initial
assessments of PaO2/FIO2 between the reintubation and success
groups.
Patients who are waiting for transplantation are usually have
severely ill and are sometimes immunocompromised. Therefore,
infections develop easily, which often postpones the transplanta-
tion. In this study, 15 (8.4%) of the 179 patients who had been
administered NIV had an infection that had been controlled
before LT. Although the LT team considered that the preoper-
ative infection had been well controlled, this factor was revealed to
be one of 3 factors predictive of reintubation following NIV. Since
the number of patients with a preoperative infection (n = 15) was
small, it was difficult to make firm conclusions as to the role of
preoperative infections in the failure of NIV. In addition to control
of preoperative infections as stringent as possible by LDLT teams,
the future study of this issue in a greater number of patients should
be done.
Prognosis of ABO-incompatible LT in adults has been reported
to be inferior to compatible LT because of rejection, and especially
there has been a high incidence of acute bile duct and vascular
complications [27]. Although it is difficult to determine the
contributions of ABO-incompatible LT to reintubation following
NIV, results of this study suggest that patients with NIV following
ABO-incompatible LT should be cautiously observed for PRCs,
which might be influenced by several complications due to an
ABO-incompatible LT.
A report from hematological parts showed that NIV treatment
for respiratory failure with acute lung injury (ALI) or ARDS had a
high mortality rate [17]. In the present report, the number of
patients with ALI/ARDS was small and pneumonia prior to NIV
treatment following LT was a significant risk factor for reintuba-
tion. In the success group and reintubated patients with
pneumonia prior to NIV, the baseline PaO2/FIO2 was similar,
whereas PaO2/FIO2 at the initial assessment after NIV therapy
was higher in the success group than in the reintubation group.
Pneumonia was already identified as a risk factor for NIV failure
[28]. Therefore, we propose that if the PaO2/FIO2 does not
improve in patients with pneumonia after application of NIV,
reintubation should be performed early. However in this study,
PaO2/FIO2 was not true but the calculated ones from the formula
[20]. Therefore, the findings on PaO2/FIO2 in pneumonia
patients in this study were not conclusive and this issue requires
further study.
Our inclusion in the analysis of the 19 patients who were
reintubated following LDLT and were then provided NIV after
their second extubation might be questioned as those patients
could be considered to represent a separate group of NIV post-
transplant recipients. However, we included these patients in the
overall analysis because we wanted to provide information for
clinicians on all of our patients who received NIV treatment
Table 4. Univariate analysis of factors related to reintubation.
OR 95% CI p value
Preoperative status
Residence in ICU with
intubation before LDLT
3.6 1.4 to 8.8 0.006




4.2 1.4 to 12.4 0.009
Operative status
ABO compatibility
Incompatible 2.5 1.2 to 5.3 0.01
Postoperative status
APACHE II 1.2 1.1 to 1.3 0.0004
Hb 0.7 0.6 to 0.9 0.007
Serum total bilirubin 1.1 1.1 to 1.2 ,0.0001
Serum CRP 1.1 1.0 to 1.2 0.008
Serum Na 0.9 0.8 to 1.0 0.02
HR 1.0 1.0 to 1.1 0.002
RR 1.1 1.0 to 1.1 0.01
Reintubation before NIV 3.3 1.3 to 8.9 0.02




4.0 1.6 to 9.8 0.002
Respiratory rate $25
breaths/min
2.4 1.0 to 5.7 0.04
NIV setting
Oxygen flow (l/min) 1.1 1.0 to 1.2 0.04
Abbreviations: OR, Odds ratio; 95%CI, 95% Confidence Interval; ICU, Intensive
Care Unit; LDLT, living-donor liver transplantation; MELD, model for end-stage
liver disease; APACHE II, Acute Physiology and Chronic Health Evaluation II; Hb,
hemoglobin; CRP, C reactive protein; Na, sodium; HR, heart rate; RR, respiratory
rate; NIV, noninvasive ventilation.
doi:10.1371/journal.pone.0081417.t004
Table 5. Multivariate forward logistic regression analysis for
reintubation.
OR 95% CI p value
Controlled preoperative infectious disease 8.9 1.6 to 48.1 0.01
ABO compatibility: Incompatible 4.5 1.5 to 13.4 0.007
Postoperative pneumonia on NIV 3.3 1.0 to 11.0 0.04
R square of the model 0.299
Abbreviations: OR, Odds ratio; 95%CI, 95% Confidence Interval; NIV, noninvasive
ventilation.
doi:10.1371/journal.pone.0081417.t005
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following LDLT. To determine if risk factors for reintubation
following LDLT differed among these 19 patients from those in
the overall study group, we performed a separate analysis and
found that the same three risk factors existed for these patients as
for the overall study group.
In our study, 16 patients were NIV intolerant. Seven of these
patients were eventually reintubated and 5 of the 7 died.
Ambrosino et al. reported that intolerance to NIV treatment
was associated with NIV failure [29]. Thus, new equipment such
new types of masks [30,31] or new types of machines that alleviate
the discomfort due to ventilator-related pressure or flow might be
helpful to decrease the rate of intolerance to NIV.
Recently, the first review of NIV in adult liver transplantation
was published [32]. Although this report was comprehensive
regarding the usefulness of NIV during the perioperative LDLT
stage, risk factors for reintubation following NIV treatment were
not discussed, which is the topic of the current report. Previously,
although we addressed the general effectiveness of NIV in both
adult and infant patients [18–21,24,25], this report provides more
specific information on the topic than those reports or the recent
review. This retrospective study was done in an institution with
extensive experience in the use of NIV [2], and the relatively high
rate of use of NIV treatment could be explained by the high mean
MELD scores (24.2) in the 179 patients whose data were analyzed.
Although these study patients already had relatively severe
morbidity before they underwent LDLT, the rate of NIV success
was 76.0%. This rate was higher or equivalent to that in
immunosuppressed patients in previous reports [10,13,14]. In
our institution, we set relatively mild inclusion criteria for
introducing NIV, and started NIV early, partly because non-
infectious respiratory complications in the patients following liver
transplantation were reported as the independent risk factors of
pneumonia [5] and respiratory failure might deteriorate rapidly in
immunosuppressed patients after LDLT. The early introduction of
NIV might result in the higher the rate of NIV success and lower
hospital mortality rate.
This study had several limitations. Firstly, was the retrospective
design. However, the large number of cases included in our
analysis was probably sufficient to minimize this limitation.
Secondly, based on several factors present in the perioperative
stage, patients in the reintubated group had a more serious
condition than those in the NIV success group. Therefore, success
or failure might be dependent on the patients’ condition before
NIV treatment. It is difficult to know how these conditions before
NIV treatment influenced the success or failure of the NIV
treatment. These complicated backgrounds might have caused the
R square in the multivariate forward logistic analysis for
reintubation to be comparatively low (Table 5). However, it is
important to manage NIV treatment so that success is achieved
without its overuse.
In conclusion, we demonstrated that controlled preoperative
infections, ABO blood type incompatibility, and postoperative
pneumonia prior to the start of NIV were early predictors of NIV
failure. We also revealed that in patients with postoperative
pneumonia being administered NIV, PaO2/FIO2 at the initial
assessment after NIV therapy was higher in the success group than
in the reintubation group. We propose that if patients with a
preoperative infection, ABO-incompatibility or post-operative
pneumonia receiving NIV do not show improvement in the
PaO2/FIO2 after NIV, early endotracheal intubation with
mechanical ventilation should be considered as an alternative
therapy.
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